Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Recommendation of “Buy” from Analysts

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has been given a consensus rating of “Buy” by the ten brokerages that are covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $17.56.

TRVI has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $12.50 price objective on shares of Trevi Therapeutics in a report on Wednesday, March 19th. B. Riley reaffirmed a “buy” rating and set a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Oppenheimer upped their price objective on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a report on Wednesday, March 19th.

Insider Buying and Selling

In other news, insider Farrell Simon sold 81,313 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the sale, the insider now directly owns 76,900 shares in the company, valued at $519,075. This represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 24.37% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Trevi Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its holdings in shares of Trevi Therapeutics by 220.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock worth $336,000 after buying an additional 69,167 shares in the last quarter. Geode Capital Management LLC boosted its stake in Trevi Therapeutics by 10.2% during the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock worth $4,223,000 after acquiring an additional 117,418 shares in the last quarter. Barclays PLC grew its holdings in Trevi Therapeutics by 180.8% in the third quarter. Barclays PLC now owns 95,232 shares of the company’s stock worth $319,000 after purchasing an additional 61,317 shares during the period. State Street Corp increased its stake in Trevi Therapeutics by 5.9% in the third quarter. State Street Corp now owns 952,912 shares of the company’s stock valued at $3,183,000 after purchasing an additional 53,051 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after purchasing an additional 6,764 shares in the last quarter. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Stock Performance

TRVI opened at $6.40 on Tuesday. Trevi Therapeutics has a 52 week low of $2.30 and a 52 week high of $7.39. The company has a fifty day moving average price of $4.65 and a two-hundred day moving average price of $3.78. The firm has a market capitalization of $491.94 million, a PE ratio of -14.55 and a beta of 0.90.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. Equities analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.